‘Evaluation of adverse prognostic gene alterations & MRD positivity in BCR::ABL1-like B-lineage acute lymphoblastic leukaemia patients, in a resource-constrained setting

[1]  A. Rosenwald,et al.  The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms , 2022, Leukemia.

[2]  A. Płotka,et al.  BCR/ABL1-Like Acute Lymphoblastic Leukemia: From Diagnostic Approaches to Molecularly Targeted Therapy , 2021, Acta Haematologica.

[3]  S. Naseem,et al.  PHi-RACE: PGIMER in-house rapid & cost effective classifier for the detection of BCR-ABL1-like acute lymphoblastic leukaemia in Indian patients , 2021, Leukemia & lymphoma.

[4]  S. Naseem,et al.  Characterization of Immunophenotypic Aberrancies with Respect to Common Fusion Transcripts in B-Cell Precursor Acute Lymphoblastic Leukemia: A Report of 986 Indian Patients , 2021, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[5]  D. Lad,et al.  Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort , 2021, Annals of Hematology.

[6]  A. Trehan,et al.  The frequency, hematological characteristics, and end-of induction residual disease in B-acute lymphoblastic leukemia with BCR-ABL1-like chimeric gene fusions in a high-risk cohort from India , 2021, Leukemia & lymphoma.

[7]  J. Ribera.  Philadelphia chromosome-like acute lymphoblastic leukemia. Still a pending matter , 2020, Haematologica.

[8]  M. Loh,et al.  Outcomes of Patients with CRLF2-Overexpressing Acute Lymphoblastic Leukemia without Down Syndrome: A Report from the Children's Oncology Group , 2020 .

[9]  R. Foà,et al.  Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913 , 2020, Haematologica.

[10]  G. Chatterjee,et al.  NARASIMHA: Novel Assay based on Targeted RNA Sequencing to Identify ChiMeric Gene Fusions in Hematological Malignancies , 2020, Blood Cancer Journal.

[11]  S. Mercadal,et al.  A novel targeted RNA-Seq panel identifies a subset of adult patients with acute lymphoblastic leukemia with BCR-ABL1-like characteristics , 2020, Blood Cancer Journal.

[12]  L. Muffly,et al.  The Current Genomic and Molecular Landscape of Philadelphia-like Acute Lymphoblastic Leukemia , 2020, International journal of molecular sciences.

[13]  G. Chatterjee,et al.  A High‐Sensitivity 10‐Color Flow Cytometric Minimal Residual Disease Assay in B‐Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2‐in‐106 and Is Superior to Standard Minimal Residual Disease Assay: A Study of 622 Patients , 2020, Cytometry. Part B, Clinical cytometry.

[14]  R. Foà,et al.  BCR/ABL1–like acute lymphoblastic leukemia: How to diagnose and treat? , 2019, Cancer.

[15]  K. Hatanaka,et al.  Quantitative detection of IKZF1 deletion by digital PCR in patients with acute lymphoblastic leukemia , 2018, International journal of laboratory hematology.

[16]  O. Soldatkina,et al.  Application of Real-Time PCR for the Detection of BCR-ABL1-like Group in Pediatric Acute Lymphoblastic Leukemia Patients , 2018, Blood.

[17]  M. Loh,et al.  Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children's Oncology Group. , 2018, Blood.

[18]  Minu Singh,et al.  Keeping PACE with Ph Positive to Ph-Like Detection in B-Lineage Acute Lymphoblastic Leukemia: A Practical and Cost Effective (PACE) Approach in a Resource Constrained Setting , 2018, Indian Journal of Hematology and Blood Transfusion.

[19]  V. Nardi,et al.  Laboratory testing in BCR‐ABL1‐like (Philadelphia‐like) B‐lymphoblastic leukemia/lymphoma , 2018, American journal of hematology.

[20]  O. Elemento,et al.  Rapid identification of BCR/ABL1‐like acute lymphoblastic leukaemia patients using a predictive statistical model based on quantitative real time‐polymerase chain reaction: clinical, prognostic and therapeutic implications , 2018, British journal of haematology.

[21]  M. Lejman,et al.  Surface expression of Cytokine Receptor-Like Factor 2 increases risk of relapse in pediatric acute lymphoblastic leukemia patients harboring IKZF1 deletions , 2018, Oncotarget.

[22]  M. Loh,et al.  Philadelphia chromosome-like acute lymphoblastic leukemia. , 2017, Blood.

[23]  E. Nievergall,et al.  High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment , 2017, Haematologica.

[24]  M. Loh,et al.  Targetable kinase gene fusions in high-risk B-ALL: a study from the Children's Oncology Group. , 2017, Blood.

[25]  S. Izraeli,et al.  BCR-ABL (Ph)-like acute leukemia-Pathogenesis, diagnosis and therapeutic options. , 2017, Blood reviews.

[26]  C. Mullighan,et al.  Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults. , 2017, Blood.

[27]  W. Hiddemann,et al.  Adults with Philadelphia chromosome–like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis , 2017, Haematologica.

[28]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[29]  R. Marwaha,et al.  Characterization of immunophenotypic aberrancies in adult and childhood acute lymphoblastic leukemia: A study from Northern India. , 2016, Journal of cancer research and therapeutics.

[30]  R. Foà,et al.  CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities. , 2016, Leukemia research.

[31]  D Rizopoulos,et al.  Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study , 2016, Leukemia.

[32]  M. D. Den Boer,et al.  Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse rates , 2015, Haematologica.

[33]  E. Mejstrikova,et al.  Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia , 2015, Haematologica.

[34]  C. Mullighan.  The genomic landscape of acute lymphoblastic leukemia in children and young adults. , 2014, Hematology. American Society of Hematology. Education Program.

[35]  K. Horibe,et al.  IKZF1 and CRLF2 gene alterations correlate with poor prognosis in Japanese BCR‐ABL1‐negative high‐risk B‐cell precursor acute lymphoblastic leukemia , 2013, Pediatric blood & cancer.

[36]  K. Horibe,et al.  IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan , 2013, Cancer medicine.

[37]  J. Soulier,et al.  Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia , 2013, Haematologica.

[38]  M. Schrappe,et al.  Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia , 2012, Leukemia.

[39]  R. Foà,et al.  IKAROS Deletions Dictate a Unique Gene Expression Signature in Patients with Adult B-Cell Acute Lymphoblastic Leukemia , 2012, PloS one.

[40]  A. Trehan,et al.  Incidence of Common Chimeric Fusion Transcripts in B-Cell Acute Lymphoblastic Leukemia: An Indian Perspective , 2012, Acta Haematologica.

[41]  M. Loh,et al.  Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. , 2012, Blood.

[42]  S. Shen,et al.  Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases , 2012, Leukemia.

[43]  Takashi Akasaka,et al.  Presence of the P2RY8-CRLF2 rearrangement is associated with a poor prognosis in non-high-risk precursor B-cell acute lymphoblastic leukemia in children treated according to the ALL-BFM 2000 protocol. , 2010, Blood.

[44]  J. Downing,et al.  Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. , 2010, Blood.

[45]  A. Veerman,et al.  IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL , 2010, Leukemia.

[46]  D. Campana,et al.  Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia. , 2010, Blood.

[47]  P. D. Dal Cin,et al.  Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia , 2009, Proceedings of the National Academy of Sciences.

[48]  R. Foà,et al.  Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). , 2009, Blood.

[49]  Christopher B. Miller,et al.  BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros , 2008, Nature.

[50]  Sanjay Jain,et al.  Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting , 2007, Leukemia & lymphoma.